Apotex: Amgen's Biosimilar Injunction An 'Abuse Of Discretion'
This article was originally published in Scrip
A Florida district judge's decision to grant a preliminary injunction (PI) to Amgen Inc. against Apotex Inc. preventing it from marketing its biosimilar of Neulasta (pegfilgrastim) was an "abuse of discretion" and amounts to a de facto 180-day extension of the 12-year exclusivity protection for innovator drugs provided by the Biologics Price Competition and Innovation Act (BPCIA), the latter company said in newly filed court documents.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.